Trade LTGO stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Latigo Biotherapeutics, Inc. (LTGO) is trading at US$22.55, down 5.77% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$1.41B. Over the past 52 weeks, LTGO has traded between US$17.22 and US$25.93. On Syfe you can trade LTGO with $0 commission and add it to your watchlist.
| Previous close | US$23.93 |
|---|---|
| Market cap | US$1.41B |
| 52-week range | US$17.22 – US$25.93 |
| Volume | 1.49M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded by Bryan Moyer on November 20, 2018 and is headquartered in Thousand Oaks, CA.
Year: 2026
Latigo Biotherapeutics, Inc. (LTGO) stock is trading at US$22.55, -5.77% from the previous close of US$23.93.
The market cap for Latigo Biotherapeutics, Inc. (LTGO) stock is approximately US$1.41B.
The 52-week high for Latigo Biotherapeutics, Inc. (LTGO) stock is US$25.93.
The 52-week low for Latigo Biotherapeutics, Inc. (LTGO) stock is US$17.22.
Latigo Biotherapeutics, Inc. (LTGO) does not currently pay a dividend.
Stay on top of LTGO
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
